Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myrecil for genitourinary syndrome of menopause
ACTRN12624000510549Phase 2Not yet recruiting
- Sponsor
- Weir Science
- Start
- May 2024
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in vaginal atrophy comparing Myrecil with Placebo (2 arms). Primary endpoints: Change from baseline to Day 56 in composite vaginal symptom score and Change from baseline to Day 56 in vaginal health. Planned start May 2024; status: not yet recruiting.
02
Drugs
Myrecil
03
Conditions
vaginal atrophy
Beyond the preview
Go deeper on ACTRN12624000510549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000510549.